news
Reactions to the EU Referendum
24 June 2016 | By Victoria White, Digital Content Producer
The BioIndustry Association and EFPIA have reacted to the news that Britain has voted to leave the European Union (EU)...
List view / Grid view
Regs & Legs
article
EU Referendum: Tell us what you think…
20 June 2016 | By Caroline Richards, Editor, Drug Target Review
As Britons go to polling stations to vote in the EU Referendum, we can't help but wonder how you feel...
news
Celyad gets patent for TCR-deficient CAR T-cell method
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
article
Health and Safety Law – Avoid falling off a ladder and into the dock
Health and Safety Law rarely arouses interest, either amongst companies or lawyers, yet its importance is growing and it has become the area in which companies and their directors are likely to find themselves in the dock, facing a criminal prosecution.
article
Companion Diagnostics: Challenges in the development of pharmacist-based point-of-care tests
A 2010 overview article on companion diagnostics, compiled by authors Stephen Naylor and Toby Cole, commented on the need for the companion diagnostic to fit into the logistics of the testing laboratory. The intervening five years have shown that patients are demanding more rapid and more convenient testing for diagnosis,…
article
When 0.77% is greater than 1%: salutatory lessons from the Court of Appeal
All new drugs rely, to a greater or lesser extent, on pre-existing research and development. Much of this pre-existing research will have resulted in patented methods and products. A major challenge for all researchers is therefore to develop new drugs which do not infringe other company’s patents.
news
Domainex granted US and EU patents for its lead programme, targeting IKK epsilon and TBK1
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
news
Cardio3 BioSciences receives Notice of Allowance for first U.S. patent broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen receptor
8 April 2015 | By Victoria White
Cardio3 has received a Notice of Allowance from the USPTO for a patent application covering TCR-deficient T-Cells which are engineered to express a CAR...
news
Key TxCell patent to be granted in the US for its lead product Ovasave(R)
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
news
Key bioelectronic medical patent for cancer treatment issued by the U.S. Patent & Trademark Office
11 February 2015 | By Cancer-Code Corporation
Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
news
SciFluor Life Sciences awarded U.S. Patent for KCNQ2/3 activator designed for treatment of epilepsy and related neurological disorders
8 January 2015 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...
news
Key US patents granted for GPCR-focused drug discovery platform arising from pioneering research and translational expertise at MRC and MRC Technology
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
news
SciFluor Life Sciences Awarded U.S. Patent for Integrin αvβ3 Inhibitors designed for the topical treatment of retinal disease
8 December 2014 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,901,144 with claims covering the novel compound SF0166...
news
Gilead announces new agreement with Medicines Patent Pool for access to medicines in developing world countries
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...
